Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Residents of New Haven can access the full range of FDA-approved GLP-1 receptor agonist medications through licensed online telehealth consultations. These medications have been clinically proven to support significant weight loss and improve metabolic health markers when prescribed as part of a comprehensive treatment plan.[1][2]
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 4, 2026
The most widely prescribed GLP-1 for both type 2 diabetes and chronic weight management in New Haven.
The newest dual GIP/GLP-1 receptor agonist offering enhanced results for eligible patients in CT.
A well-established daily GLP-1 option for chronic weight management available to New Haven patients.
The following New England Journal of Medicine clinical trials provide the foundational evidence base for all FDA-approved GLP-1 receptor agonists currently available through telehealth:
GLP-1 receptor agonists are not controlled substances under DEA scheduling. They may be prescribed via telehealth consultation under Connecticut law after a valid clinical evaluation by a CT-licensed physician.
Getting started with GLP-1 medication in New Haven, Connecticut is simple. Our telehealth platform connects you with licensed CT physicians who specialize in metabolic health and weight management.
Fill out a secure, HIPAA-compliant health questionnaire covering your metabolic history, comorbidities, medication list, and clinical objectives. The prescribing physician uses this comprehensive intake to assess eligibility and design an appropriate GLP-1 treatment protocol.
A board-certified, CT-licensed physician reviews your profile and conducts a telehealth consultation. They will discuss treatment options, potential side effects, and create a personalized GLP-1 treatment plan tailored to your needs.
If approved, your GLP-1 prescription is sent to a licensed US pharmacy. Your medication ships directly to your New Haven address, typically arriving within 3-5 business days in discreet, temperature-controlled packaging.
Your provider schedules regular follow-up consultations to monitor your progress, adjust dosing as needed, and ensure optimal results. Continuous medical oversight is included throughout your treatment in New Haven.
Our telehealth providers serve all neighborhoods across New Haven, CT. Select your neighborhood for localized information about GLP-1 medication access.
Telehealth has transformed access to GLP-1 medications for New Haven residents. Instead of scheduling appointments at local clinics, waiting weeks for availability, and making multiple office visits, you can complete the entire process from home.
Our network of CT-licensed physicians specializes in GLP-1 prescribing and weight management. Every consultation is thorough, every prescription is legitimate, and every medication is sourced from licensed US pharmacies. Whether you live in central New Haven, Amity, or Annex, you receive the same high-quality medical care.
Residents of cities near New Haven can also access GLP-1 telehealth services through our provider network.
Explore GLP-1 telehealth services in the largest cities across Connecticut.
Our physician network provides GLP-1 telehealth consultations to patients in every major metropolitan area in the country.
Local weight loss and GLP-1 providers serving the New Haven, CT area, based on Google Business listings.
Washington Medical Center, 52 Washington Ave %232, North Haven, CT 06473
(203) 672-2840
5/5 ★ (4 reviews)
Visit website →109 Boston Post Rd, Orange, CT 06477
(203) 772-8345
4.6/5 ★ (60 reviews)
Visit website →Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Complete a brief online health assessment, consult with a licensed CT physician via telehealth, and if eligible, receive your GLP-1 prescription delivered to your New Haven address within 3-5 business days.
Yes. Telehealth prescribing of GLP-1 medications is fully legal in Connecticut when conducted by a CT-licensed physician through a HIPAA-compliant platform after a proper medical evaluation.
Initial eligibility assessments are free. Consultation and medication costs vary depending on the prescribed GLP-1 medication and your insurance coverage. Many savings programs and manufacturer coupons are available to reduce out-of-pocket costs.
Both semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved for chronic weight management and show excellent results. Your physician will recommend the most appropriate medication based on your individual health profile, goals, and medical history.
No. The entire process is conducted online through secure telehealth. You do not need to visit a doctor's office, clinic, or pharmacy in New Haven. Your medication is delivered directly to your home.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
